An Early Phase 1 interventional study of ECP Methoxsalen and Standard of Care in Chronic Graft Versus Host Disease, sponsored by Mallinckrodt. Completed at 32 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-02-19.
Sponsored by Mallinckrodt · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 108th largest by enrollment of the 260 interventional ones that give a count, is one of 15 that started in 2011, is one of 30 in phase 1, and was the 87th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Sarah Nikiforow, MD · Sites in United States
Ages 2+
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 117 · Phase 3 33 · Phase 4 18
First in 2001; this study’s year is marked. 15 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 45 across the 260 interventional studies, 187 across the 39 observational. Of the 209 that completed or were terminated, 110 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 300 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
Keenova Therapeutics plc has 1 study filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Bronchiolitis Obliterans Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT07395232Phase 3Dompé Farmaceutici S.p.AAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC | 2027-03 |
| NCT02181257Phase 3Washington University School of MedicineExtracorporeal Photopheresis for Medicare Recipients of Lung Allografts | 2027-04 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06018766Steven Hays, MDLAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.
Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. The machine removes the white blood cells, mixes them with a light-sensitive drug, shines light on it, and puts all the blood back in.
This study will find out if patients respond better if they get ECP with methoxsalen, in addition to the pills normally used to treat cGVHD.
The investigation of extracorporeal photopheresis (ECP) plus standard of care (SoC) (SoC+ECP) in chronic graft-versus-host disease (cGVHD) within prospective, randomized clinical studies is limited, despite its frequent clinical use.
This phase 1/pilot study was the first randomized, prospective study to investigate ECP use as first-line therapy in cGVHD, based on the 2015 National Institutes of Health (NIH) consensus criteria for diagnosis and response assessment.
Adult patients with new-onset (≤3 years of hematopoietic stem cell transplantation) moderate or severe cGVHD were randomized 1:1 to 26 weeks of SoC+ECP vs SoC (corticosteroids and cyclosporine A/tacrolimus) between 2011 and 2015. The primary endpoint was overall response rate (ORR), defined as complete or partial response, at week 28 in the intention-to-treat population (ITT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for inclusion in this trial, the patient must have moderate to severe chronic [defined by the National Institutes of Health (NIH) 2015 Consensus Criteria] that started within 3 years after hematopoietic stem cell transplantation ().
Exclusion Criteria:
Has infections and/or requires treatment that (per protocol or in the opinion of the investigator) might compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive methoxsalen administered via ECP in addition to standard of care
Drug: ECP Methoxsalen · Drug: Standard of Care
Participants receive standard of care only
Drug: Standard of Care
Methoxsalen delivered by ECP
Also known as: Uvadex, Extracorporeal photopheresis (ECP)
Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
Also known as: Reference therapy
Number of Participants With an Overall Response at Week 28
Participants with overall response included those with partial response or complete response, according to study staff who did not know which treatment they received (blinded assessment).
Time frame: Week 28
Patients were enrolled in Austria, France, Germany, Italy, Hungary, Spain, the United Kingdom, and the United States. Enrollment started in November 2011, and the last patient visit occurred in March 2015.
| Milestone | ECP Methoxsalen + SoC | Standard of Care (SoC) |
|---|---|---|
| Started | 29 | 31 |
| Baseline population | 29 | 31 |
| Safety population | 28 | 28 |
| Intent-to-treat population | 29 | 24 |
| Completed | 22 | 16 |
| Not completed | 7 | 15 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Study site closed | 0 | 5 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 3 |
Participants with overall response included those with partial response or complete response, according to study staff who did not know which treatment they received (blinded assessment).
| Participants | ECP Methoxsalen + SoC | Standard of Care (SoC) |
|---|---|---|
| Number of Participants With an Overall Response at Week 28 | 20 | 14 |
Collected over Treatment emergent adverse events were recorded from the start of treatment through Week 28.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ECP Methoxsalen + SoC | 4/29 (13.8%) | 8/28 (28.6%) | 26/28 (92.9%) |
| Standard of Care (SoC) | 0/31 (0%) | 9/28 (32.1%) | 24/28 (85.7%) |
| Event | ECP Methoxsalen + SoC | Standard of Care (SoC) |
|---|---|---|
| SepsisInfections and infestations | 2/28 | 1/28 |
| MyopathyMusculoskeletal and connective tissue disorders | 0/28 | 2/28 |
| Cardiac FailureCardiac disorders | 0/28 | 1/28 |
| Thyroiditis subacuteEndocrine disorders | 1/28 | 0/28 |
| Graft versus host disease in liverImmune system disorders | 0/28 | 1/28 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/28 | 0/28 |
| Cytomegalovirus infectionInfections and infestations | 1/28 | 0/28 |
| Escherichia infectionInfections and infestations | 1/28 | 0/28 |
| Escherichia sepsisInfections and infestations | 1/28 | 0/28 |
| Herpes simplexInfections and infestations | 0/28 | 1/28 |
| Event | ECP Methoxsalen + SoC | Standard of Care (SoC) |
|---|---|---|
| HypertensionVascular disorders | 9/28 | 4/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/28 | 1/28 |
| FatigueGeneral disorders | 5/28 | 1/28 |
| Back painMusculoskeletal and connective tissue disorders | 2/28 | 5/28 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/28 | 2/28 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/28 | 4/28 |
| DiarrhoeaGastrointestinal disorders | 1/28 | 4/28 |
| Oedema peripheralGeneral disorders | 2/28 | 4/28 |
| PyrexiaGeneral disorders | 0/28 | 4/28 |
| Gamma-glutamyltransferase increasedInvestigations | 4/28 | 3/28 |
All participants enrolled and included in the safety analysis set
| Age, Customized(Participants) | ECP Methoxsalen + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| 18-44 years | 8 | 10 | 18 |
| 45-64 years | 19 | 19 | 38 |
| 65 years and over | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | ECP Methoxsalen + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Female | 7 | 13 | 20 |
| Male | 22 | 18 | 40 |
| Ethnicity (NIH/OMB)(Participants) | ECP Methoxsalen + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 24 | 24 | 48 |
| Unknown or Not Reported | 3 | 5 | 8 |
| Race/Ethnicity, Customized(Participants) | ECP Methoxsalen + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| White | 22 | 24 | 46 |
| Black | 2 | 0 | 2 |
| Asian | 0 | 0 | 0 |
| Other | 1 | 1 | 2 |
| Not Collected | 4 | 6 | 10 |
| Region of Enrollment(participants) | ECP Methoxsalen + SoC | Standard of Care (SOC) | Total |
|---|---|---|---|
| Austria | 3 | 3 | 6 |
| Hungary | 4 | 4 | 8 |
| United States | 6 | 6 | 12 |
| Italy | 0 | 3 | 3 |
| United Kingdom | 1 | 1 | 2 |
| France | 4 | 6 | 10 |
| Germany | 11 | 7 | 18 |
| Spain | 0 | 1 | 1 |
Plan to share: No
Ran from Nov 2011 to primary completion in Mar 2015, 40 months.
Results were first posted in Oct 2019, 4 years 7 months after primary completion.
Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 40 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methoxsalen
Bronchiolitis Obliterans Syndrome →